Views & Analysis | Perspectives on pharma industry issues

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Articles

Maximizing engagement in online medical communities

pharmaphorum interviews Shona Davies of MSD on the topic of online physician resources, maximising online engagement and the future of the digital space.

Articles

How will the US election affect the FDA?

Steven Grossman discusses the effect the US election, between Barack Obama and Mitt Romney, will have on the Food and Drug Administration. While FDA issues have hardly disappeared from the policy / regulatory arena, the agency has been largely invisible during...

Articles

Category Captain Management: transitioning from just a sourc...

With traditional marketing in disrepute, a new strategy is emerging that goes beyond just the physical features and attributes of a drug, discusses Bill Trombetta. Who said the following: “We are beloved by investment banks and stockholders but we are perceived by physicians and...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access